Motion Sickness (Dimenhydrinate)
Brand Names: Motion Sickness
Methodology & AI Transparency ⓘ
Motion Sickness (Dimenhydrinate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2026-06-15 designates Motion Sickness (NDC 50804-198, 11673-198, registered by Geiss, Destin & Dunn Inc.) as a over-the-counter branded histamine-1 receptor antagonist formulation of Dimenhydrinate.
- 2 Real-world patient consensus: Commercial Motion Sickness monograph (50 mg/1 Tablet) cross-indexed with generic Dimenhydrinate for therapeutic equivalence review.
- 3 Typical cash cost range: Public pharmacy ledger: $11.94 low cash benchmark vs. $34.50 chain retail average ($0.0478/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Motion Sickness (Dimenhydrinate) include nausea (11.7%), dizziness (6%), vomiting (5.3%).
Ask our AI Specialists anything about Motion Sickness (Dimenhydrinate)
Motion Sickness (Dimenhydrinate) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2026-06-15 designates Motion Sickness (NDC 50804-198, 11673-198, registered by Geiss, Destin & Dunn Inc.) as a over-the-counter branded histamine-1 receptor antagonist formulation of Dimenhydrinate. Supplied across 50 mg/1 Tablet; 25 mg/1 Tablet, Motion Sickness is utilized in Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness
Clinical pharmacology for Motion Sickness is driven by Dimenhydrinate acting within histamine-1 receptor antagonist signaling cascades with class-characteristic hepatorenal disposition. Distributed across 50 mg/1 Tablet; 25 mg/1 Tablet (NDC 50804-198, 11673-198; registered by Geiss, Destin & Dunn Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $11.94 to $34.50.
Following administration (50 mg/1 Tablet), Motion Sickness (Dimenhydrinate) achieves Approximately 51% to 63% enteral uptake across labeled Motion Sickness (Dimenhydrinate) strengths bioavailability and maximum serum exposure occurs 2–5 hours after motion sickness (dimenhydrinate) dosing onset, governed by a Steady-state plasma equilibrium reached over 3–7 hour t½ intervals for Motion Sickness (Dimenhydrinate) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar motion sickness (dimenhydrinate) conjugates.
Before initiating Motion Sickness (Dimenhydrinate) at 50 mg/1 Tablet, clinical safety checklists rule out history of severe allergic sensitivity to motion sickness (dimenhydrinate) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-06-15 dimenhydrinate labeling. Logged tolerability patterns center on nausea (11.7% of reports), headache (6.9% of reports), dizziness (6% of reports).
Verify medication reconciliation lists so Motion Sickness (Dimenhydrinate) is not inadvertently duplicated with another histamine-1 receptor antagonist.
Botanical enzyme modulators may alter oral first-pass exposure of Motion Sickness (Dimenhydrinate); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Motion Sickness (Dimenhydrinate) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-06-15 Dimenhydrinate labeling
Logged Side-Effect Incidence (13 Reports)
Motion Sickness (Dimenhydrinate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Motion Sickness (Dimenhydrinate))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Emotional changes in men treated with sildenafil citrate for erectile: What a 841-Participant Study Found The physiologic and emotional benefits of sildenafil in the treatment of ED were confirmed, overall and in men with comorbid high blood pressure, high cholesterol, benign prostatic hypertrophy, and/or depression. The journal of sexual medicine • 2009-12-15 • Randomized Controlled Trial | N = 841 | 93/100 | PMID 19796051 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjuvant Atezolizumab in Patients with Sarcomatoid kidney Cell Carcinoma: A The side effects were similar to those seen in patients with other types of kidney cancer treated with atezolizumab in the same study (IMmotion010). European urology oncology • 2024-12-15 • Phase III Randomized Trial | N = 37 | 88/100 | PMID 38955577 ↗ |
| Targeted Pain Relief Without Stomach Upset: How Well Do Diclofenac Skin Patches Work? A short-course applied to the skin diclofenac epolamine patch, combined with rehabilitation training, effectively alleviates pain, accelerates functional recovery, and is safe for treating moderate hamstring strain, supporting... Pakistan journal of pharmaceutical sciences • 2027-01-01 • Randomized Controlled Trial | N = 120 | 88/100 | PMID 42924980 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. The American journal of psychiatry • 2025-06-01 • Randomized Controlled Trial | N = 25 | 88/100 | PMID 40329640 ↗ |
| Can This Approach Help? Inside the Latest Research on A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T -scores. Journal of attention disorders • 2024-06-15 • Phase III Randomized Trial | N = 117 | 88/100 | PMID 38600754 ↗ |
Motion Sickness (Dimenhydrinate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0478/unit (~$1.43/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $11.94 / mo | View logs ↓ |
Motion Sickness (Dimenhydrinate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Motion Sickness (Dimenhydrinate) RxNorm Concept ID | 198603 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0478 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.94 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Motion Sickness (Dimenhydrinate) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Motion Sickness (Dimenhydrinate): FDA labeling (2026-06-15, NDC 50804-198), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Motion Sickness (Dimenhydrinate) community threads and patient logs by age, biological sex, dosage, and treatment duration.